ClinConnect ClinConnect Logo
Search / Trial NCT02487732

Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary Stenting

Launched by KOREA UNIVERSITY ANAM HOSPITAL · Jun 30, 2015

Trial Information

Current as of May 13, 2025

Completed

Keywords

Diabetic Patients With Non St Elevation

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Provision of informed consent prior to any study specific procedures
  • 2. Newly diagnosed type 2 diabetic patients or type 2 diabetic patients on hypoglycemic agents between the age of 30 to 70
  • 3. Non-ST elevation Acute coronary syndrome with successful coronary stent implantation (with TIMI flow grade 3 after the procedure)
  • Exclusion Criteria:
  • 1. Hypersensitivity to ticagrelor, prasugrel or any of the excipients
  • 2. No prior use of either ticagrelor or prasugrel within a month prior to randomization.
  • 3. History of intracranial bleeding at any time
  • 4. Active pathologic bleeding
  • 5. Hemoglobin A1c \>9%
  • 6. Type 1 diabetes
  • 7. Decreased serum platelet level (\< 100,000/uL)
  • 8. Need for chronic oral anticoagulant therapy or chronic low-molecular-weight heparin
  • 9. Gastrointestinal bleed within the past 6 months, or major surgery within 30 days
  • 10. Renal failure requiring dialysis or anticipated need for dialysis during the course of the study
  • 11. Any condition which in the opinion of the investigator would make it unsafe or unsuitable for the patient to participate in this study
  • 12. Involvement in the planning and/or conduct of the study
  • 13. Left ventricular ejection fraction \< 40%
  • 14. Hepatic dysfunction (aspartate aminotransferase or alanine aminotransferase \> twice the upper limit)
  • 15. Gastrointestinal disorder such as Crohn's disease
  • 16. Alcohol abuse
  • 17. Steroid or hormone replacement therapy
  • 18. Serum creatinine \> 2.0 mg/dL.
  • 19. Prior history of CVA or stroke
  • 20. Body weight \< 60 kg
  • 21. Life expectancy less than a year
  • 22. Known pregnancy, breast-feeding, or intend to become pregnant during the study period

About Korea University Anam Hospital

Korea University Anam Hospital is a leading academic medical institution in South Korea renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its state-of-the-art facilities and multidisciplinary expertise to conduct rigorous studies that aim to improve patient outcomes and contribute to medical knowledge. With a strong emphasis on ethical practices and patient safety, Korea University Anam Hospital collaborates with various stakeholders to facilitate cutting-edge research across diverse therapeutic areas, fostering an environment that promotes scientific discovery and translational medicine.

Locations

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials